系统性红斑狼疮国际协作组初始队列中狼疮肾炎的经济学评价:多状态模型方法
研究基于11国32中心系统性红斑狼疮国际协作组初始队列1545例患者,采用多状态模型比较有无狼疮肾炎患者的10年累计费用。随访期间39.4%发生狼疮肾炎;估算肾小球滤过率<30 ml/min者10年累计费用为310579加元,无狼疮肾炎且估算肾小球滤过率>60 ml/min者为19987加元,前者约为后者的15倍。
要点
- 狼疮肾炎合并估算肾小球滤过率<30 ml/min者10年累计费用310579加元,无狼疮肾炎且估算肾小球滤过率>60 ml/min者19987加元。
- 狼疮肾炎合并估算蛋白尿>3 gm/day者10年累计费用84040加元,无狼疮肾炎且估算蛋白尿<0.25 gm/day者20499加元。
- 按各肾脏状态预期持续时间乘以相应年费用,可用起病时疾病严重程度预估未来医疗费用。
核心结论
- 估算肾小球滤过率<30 ml/min的患者10年费用为估算肾小球滤过率正常者的15倍。
- 通过估算各肾脏状态预期持续时间并纳入相应年费用,可用起病时疾病严重程度预估未来医疗费用。
- 该信息对新型疗法的成本效果评价至关重要。
研究设计与样本
- 研究纳入11个国家32个中心的系统性红斑狼疮国际协作组初始队列患者,诊断后15个月内入组。
- 每年采集肾功能、住院、用药、透析及选定操作的数据。
- 狼疮肾炎经肾活检或美国风湿病学会分类标准诊断;肾功能每年用估算肾小球滤过率或估算蛋白尿评估。
- 采用多状态模型,将各肾脏状态的年费用乘以预期状态持续时间,预测10年累计费用。
主要发现
- 共1545例患者参与,89.3%为女性,诊断时平均年龄35.2±13.4岁,49%为白人,平均随访6.3±3.3年。
- 至随访结束时39.4%的患者发生狼疮肾炎。
- 狼疮肾炎且估算肾小球滤过率<30 ml/min者10年累计费用310579加元(2015年加拿大元),无狼疮肾炎且估算肾小球滤过率>60 ml/min者19987加元。
- 狼疮肾炎且估算蛋白尿>3 gm/day者10年累计费用84040加元,无狼疮肾炎且估算蛋白尿<0.25 gm/day者20499加元。
关键数值与推荐
- 狼疮肾炎诊断依据肾活检或美国风湿病学会分类标准。
- 肾功能评估采用估算肾小球滤过率或估算蛋白尿。
- 10年累计费用按各肾脏状态年费用乘以预期状态持续时间计算。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Little is known about the long-term costs of lupus nephritis (LN). The costs were compared between patients with and without LN using multistate modeling. METHODS: Patients from 32 centers in 11 countries were enrolled in the Systemic Lupus International Collaborating Clinics inception cohort within 15 months of diagnosis and provided annual data on renal function, hospitalizations, medications, dialysis, and selected procedures. LN was diagnosed by renal biopsy or the American College of Rheumatology classification criteria. Renal function was assessed annually using the estimated glomerular filtration rate (GFR) or estimated proteinuria. A multistate model was used to predict 10-year cumulative costs by multiplying annual costs associated with each renal state by the expected state duration. RESULTS: A total of 1,545 patients participated; 89.3% were women, the mean ± age at diagnosis was 35.2 ± 13.4 years, 49% were white, and the mean followup duration was 6.3 ± 3.3 years. LN developed in 39.4% of these patients by the end of followup. Ten-year cumulative costs were greater in those with LN and an estimated glomerular filtration rate (GFR) <30 ml/minute ($310,579 2015 Canadian dollars versus $19,987 if no LN and estimated GFR >60 ml/minute) or with LN and estimated proteinuria >3 gm/day ($84,040 versus $20,499 if no LN and estimated proteinuria <0.25 gm/day). CONCLUSION: Patients with estimated GFR <30 ml/minute incurred 10-year costs 15-fold higher than those with normal estimated GFR. By estimating the expected duration in each renal state and incorporating associated annual costs, disease severity at presentation can be used to anticipate future health care costs. This is critical knowledge for cost-effectiveness evaluations of novel therapies.
引用
- Barber MRW, Hanly JG, Su L, et al. Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care Res (Hoboken). 2018. PMID: 29193883. doi:10.1002/acr.23480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。